Eli Lilly remains optimistic about strong demand for its weight-loss and anti-diabetes injectable, tirzepatide (sold as Mounjaro), despite its premium pricing, even as lower-cost semaglutide generics prepare to enter the Indian market.Winselow Tucker, preside…
Mumbai: Eli Lilly is confident of sustained demand for its weight-loss and anti-diabetes drug despite premium pricing amid the imminent launch of cheaper semaglutide generics in the Indian market.The… [+5052 chars]
